Release no. 12/2008 Guidelines for incentive pay to the board of directors and executive management Referring to the notice to convene the annual general meeting enclosed please find draft general guidelines for incentive pay for the board of directors and the executive management of Pharmexa A/S. The guidelines are available at the registered office of the company, have been sent to shareholders who have requested it, and are available at the company's website. Hørsholm, March 18, 2008 Pharmexa A/S Additional information: Jakob Schmidt, Chief Executive Officer, tel +45 4516 2525 Claude Mikkelsen, Vice President, Corporate Affairs and Communication, tel +45 4516 2525 or +45 4060 2558 For the editors: Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer and serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, arthritis, bone degeneration and Alzheimer's disease, as well as infectious diseases such as HIV, influenza, hepatitis and malaria. Company programs include GV1001, a peptide vaccine that has entered Phase III trials in pancreatic cancer and Phase II trials in liver cancer, and a number of HIV and hepatitis vaccines in Phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 80 employees and is listed on the OMX Nordic Stock Exchange Copenhagen under the trading symbol PHARMX.
Guidelines for incentive pay to the board of directors and executive management
| Source: Affitech A/S
Attachments
